From a GeneMatcher-enabled international collaboration, we identified ten individuals with 77 intellectual disability, speech delay, ataxia and facial dysmorphism and a mutation in EBF3, 78 encoding a transcription factor required for neuronal differentiation. Structural assessments, 79 transactivation assays, in situ fractionation, RNA-seq and ChIP-seq experiments collectively 80 show that the mutations are deleterious and impair EBF3 transcriptional regulation. These 81 findings demonstrate that EBF3-mediated dysregulation of gene expression has profound 82 effects on neuronal development in humans. 83 84 85 ⏐ 4
⏐ 6
EBF3 encodes the early B-cell factor 3, which is one of four members of the EBF 137 transcription factor family (also known as Olf, COE, or O/E). All EBFs consist of an N-138 terminal DNA-binding domain (DBD), an IPT (Ig-like/plexins/transcription factors) domain 139 with yet unknown function, a helix-loop-helix (HLH) domain, which is critical for homo-and 140 heterodimer formation, and a C-terminal transactivation domain (TAD) (Fig. 1b) 7 . EBF1 has 141 been discovered as a key factor for B-cell differentiation 8 and olfactory nerve signaling 9 . 142 However, expression of ebf1, ebf2 and ebf3 in early post-mitotic neurons during 143 embryogenesis suggested a role in neuronal differentiation and maturation 10 . Ebf3 acts 144 downstream of the proneural transcription factor neuroD in late neural differentiation in 145 Xenopus 11 and is transcriptionally repressed by ARX 12 , abnormalities of which cause a 146 spectrum of developmental disorders ranging from ID to brain malformation syndromes 13 . 147 Silencing, genomic deletion and somatic point mutations [p.(Arg243Trp) and 148 p.(Trp265Cys)] 14, 15 of EBF3 in diverse types of cancer as well as EBF3-mediated induction of 149 cell cycle arrest and apoptosis suggest that EBF3 acts as a tumor suppressor by regulating the 150 expression of specific target genes and controlling a potential anti-neoplastic pathway 7 . All 151 germline EBF3 missense variants and the tumor-specific mutation p.(Arg243Trp) are located 152 in the DBD ( Fig. 1b and Supplementary Fig. 2) . Interaction of the DBD with DNA is 153 dependent on a zinc-coordination motif, the zinc knuckle (COE motif), located between 154 His157 and Cys170 (Supplementary Fig. 2) . Thus, the p.(His157_Ile159dup) variant most 155 likely affects DNA-binding as has been shown for the EBF3 H157A mutant 16, 17 . 156 The structural impact of the five missense mutations was explored by a homology model 157 for the DNA-bound configuration of the DBD of EBF3 with the DNA duplex containing the 158 EBF1 consensus sequence 18 . Two of the five alterations, p.(Asn66Asp) and p.(Gly171Asp), 159 were predicted to directly affect DNA binding (Supplementary Fig. 3a-c) . Pro177 is 160 localized in close proximity to the zinc finger (His157, Cys161, Cys164 and Cys170) and to 161 Asn174, which forms a hydrogen bond with DNA. Replacement of Pro177 by leucine causes Fig. 3d ). Arg209 does not directly 164 interact with DNA, but forms hydrogen bonds with the backbone of Cys198 and Asn197, the 165 latter directly interacting with DNA. The change of Arg209Trp is expected to alter 166 positioning of Asn197 and binding affinity for DNA ( Supplementary Fig. 3e ). Tyr141 is 167 localized within a loop probably involved in EBF3 dimer formation. Substitution of this 168 residue may lead to a conformational change at the dimer interface, resulting in reduced 169 stability of the EBF3 dimer and interfering with its ability to interact with DNA 170 (Supplementary Fig. 3f ).
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To analyze the functional effect of the EBF3 mutations, all mutant proteins were 172 transiently and efficiently expressed in HEK 293T cells. By confocal microscopy analysis, we 173 confirmed exclusive nuclear localization of wild-type EBF3 ( Fig. 2a) . In contrast, all but one 174 mutant protein showed nuclear localization or both nuclear and cytoplasmic distribution. Only 175 the mutant lacking 202 amino acids at the C-terminus was almost entirely mislocalized to the 176 cytoplasm ( Fig. 2a) . We next performed a reporter gene assay to assess whether EBF3 177 mutants still mediate transcriptional activation of the target gene CDKN1A (p21) 16 . Similar to 178 p53, for which CDKN1A is a prototypical target gene, expression of wild-type EBF3 179 markedly increased the reporter activity driven by the CDKN1A promoter ( Fig. 2b) . In 180 contrast, EBF3 mutants had significantly reduced or no ability to activate transcription of the 181 reporter gene (Fig. 2b) . CDKN1A promoter activation was not significantly reduced when 182 EBF3 WT was co-expressed with either of the mutants p.Gly171Asp, p.Pro177Leu and 183 p.Arg209Trp (Supplementary Fig. 4a ). In contrast, co-expression of wild-type EBF3 and 184 each of the mutants p.Asn66Asp, p.Tyr141Cys, p.His157_Ile159dup, p.Arg303*, and 185 p.Gln305* caused a significant reduction in reporter activity by 40-50% ( Supplementary Fig.   186 4a), suggesting a potential dominant-negative impact of these mutations on the wild-type 187 allele. The dominant-negative effect was also observed when expressing increasing amounts 195 To study interaction of EBF3 mutants with chromatin, we performed in situ subcellular indicating that in contrast to EBF3 mutants the wildtype is tightly associated with chromatin 204 ( Fig. 2c) . 205 To further test the hypothesis that the EBF3 variants impact EBF3 DNA-binding and 206 have regulatory consequences, we transfected SK-N-SH cells with EBF3 WT and EBF3 P177L 207 cDNA overexpression constructs, stably selected the cells for integration and expression, and neurodevelopmental pathways. Overall, analyses of the SK-N-SH EBF3 WT and EBF3 P177L 215 transcriptomes indicate that EBF3 targets a wide variety of genes and the p.Pro177Leu 216 mutation leads to a reduction in the extent of EBF3-mediated gene regulation.
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To determine if EBF3 P177L affects binding of EBF3 across the genome, we performed 218 chromatin immunoprecipitation coupled with massively parallel sequencing (ChIP-seq) in 219 both EBF3 WT and EBF3 P177L transfected SK-N-SH cells. There were 21,046 binding sites 220 identified for EBF3 WT and 4,193 binding sites for EBF3 P177L , of which 4,081 were shared 221 ( Fig. 3c ) -i.e., EBF3 P177L binds to a subset of EBF3 WT binding sites. MEME-Suite motif 222 analysis 19 identified an enrichment for the canonical EBF zinc binding motif in called peaks 223 from both wild-type and mutant protein expressing lines ( Fig. 3c) . We then investigated 224 whether or not EBF3 WT binding sites in our ChIP-seq data were enriched for closer proximity 225 to gene transcriptional start sites (TSS) than EBF3 P177L binding sites. Compared to EBF3 P177L , 226 EBF3 WT binding sites were significantly more likely to reside near gene TSSs (K-S p<0.05) 227 and genes differentially expressed in EBF3 WT were enriched for closer proximity to binding 228 site peaks than non-significant genes ( Fig. 3d) . To determine if EBF3 WT proximal binding 229 sites have some functional transcriptional consequence that is altered by the p.Pro177Leu 230 mutation, we compared log 2 fold-changes for EBF3 WT significantly differentially expressed 231 genes with a TSS within 5 kb of shared EBF3 WT and EBF3 P177L binding sites. These genes 232 had comparatively smaller log 2 fold-changes in EBF3 P177L samples relative to EBF3 WT ( Fig.   233 3e), indicating that the p.Pro177Leu mutation appears to lead to reduced transcriptional 234 alteration. Taken together, these findings are consistent with EBF3 acting as a proximal 235 regulator of transcription at cis-regulatory sequences and supports the hypothesis that 236 EBF3 P177L has reduced function due to partial disruption of the DNA-binding domain.
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In conclusion, our results show that de novo mutations disrupting the regulatory functions 238 of the conserved neurodevelopmental transcription factor EBF3 underlie a new syndrome of 239 intellectual disability, ataxia and facial dysmorphism. This phenotype, while rare, is a ⏐ 10 substantial contributor to intellectual disability. Two patients studied here were found in a 241 single Clinical Sequencing Exploratory Research study 20 on a series of 317 unrelated families. 242 Additionally, 5 de novo protein altering variants (2 missense, 1 frameshift, 2 splice) in EBF3 243 have recently been reported in a series of 4,293 families with individuals with developmental 244 disorders, although neither these variants nor EBF3 were discussed nor concluded to be 245 pathogenic (preprint data available at http://biorxiv.org/content/early/2016/04/22/049056).
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Both missense variants are located in the DNA-binding domain of EBF3 and one, 247 p.(Pro177Leu), is identical to a mutation in this study, indicating mutational recurrence.
248
Combining these observations with our own analyses indicates that mutations in EBF3 may 249 underlie more than 1 in 1,000 individuals affected with otherwise unexplained developmental Epifluorescence microscopy analysis was performed in HEK 293T cells transiently 332 expressing wild-type or mutant EBF3 (green). Nuclei were stained with DAPI (blue). Wild-333 type EBF3 is exclusively localized in the nucleus, while the DNA-binding deficient mutant 334 EBF3 H157A and the disease-associated mutants EBF3 N66D , EBF3 Y141C , EBF3 G171D , 335 EBF3 H157_I159dup , EBF3 P177L , EBF3 R209W, and EBF3 R303* are also located in the cytoplasm. Captured libraries were then loaded onto the HiSeq2000 or 2500 platform (Illumina).
Trimmomatic was employed to remove adapters, low quality (phred quality score < 5) bases from the 3' ends of sequence reads 2 . Cutadapt was used for subject 10. Reads shorter than 36 bp were subsequently removed. Further processing was performed following the Genome Analysis Toolkit's (GATK) best practice recommendations. Briefly, trimmed reads were aligned to the human reference genome (UCSC GRCh37/hg19) using the Burrows-Wheeler Aligner (BWA mem v0.7.12). Duplicate reads were marked with Picard tools (v1.141).
GATK (v3.4) was employed for indel realignment, base quality score recalibration, calling variants using the HaplotypeCaller, joint genotyping, and variant quality score recalibration.
AnnoVar (v2015-03-22) was used to functionally annotate and filter alterations against public databases (dbSNP138, 1000 Genomes Project, and ExAC Browser). Exonic variants and intronic alterations at exon-intron boundaries ranging from -10 to +10, which were clinically associated and unknown in public databases, were retained. Whole-exome sequencing and data analysis for families 2, 3, and 6 was performed at GeneDx as described previously 3 . For families 7 and 8, WES and data analysis were performed in Human Genome Sequencing Center (HGSC) at Baylor College of Medicine, according to the previously described protocol and using notably the VCRome capture reagent [4] [5] [6] ; WES targeted the coding exons of ~20,000 genes with 130X average depth-of-coverage and greater than 95% of the targeted bases with >20 reads 4-6 .
Subjects 5 and 6 (families 4 and 5) were identified as part of a trio-based clinical sequencing study at HudsonAlpha, which to date has performed sequencing on 349 affected probands from 317 families. Genomic DNA was isolated from peripheral blood leukocytes and exome sequencing was conducted to a median depth of ~65X with at least 80% of targeted bases covered at 20X. Exome capture was completed using Nimblegen SeqCap EZ Exome version 3 and sequencing was conducted on the Illumina HiSeq 2000. Reads were aligned to reference hg19 using bwa (0.6.2) 7 . GATK best practice methods 8 were used to identify variants, with samples called jointly in batches of 10-20 trios. Maternity and paternity of each parent was confirmed by whole exome kinship coefficient estimation with KING 9 . De novo variants were identified as heterozygous variant calls in the proband in which there were at least 10 reads in both parents and the proband, an alternate allele depth of at least 20% in the proband and less than 5% in each parent, and a minor allele frequency <1% in 1000 Genomes and ExAC. All candidate de novo variants that either affected a protein or had a scaled CADD score > 10 (ref. 10 ) were manually reviewed, as were variants similarly identified using X-linked, compound heterozygote, and recessive inheritance filters. In each patient described, no other variants were identified as potentially disease-causal.
Variant validation. Sequence validation and segregation analysis for all candidate variants
were performed by Sanger sequencing. Primer pairs designed to amplify selected coding exons of the EBF3 gene and exon-intron boundaries (NM_001005463.2) and PCR conditions are available on request. For families 1 and 9, amplicons were directly sequenced using the ABI BigDye Terminator Sequencing Kit (Applied Biosystems) and an automated capillary sequencer (ABI 3500; Applied Biosystems). Sequence electropherograms were analysed using Sequence Pilot software (JSI medical systems). For families 4, 5, 7 and 8, Sanger confirmation of variants, including confirmation of absence from both biological parents, was performed by a CAP/CLIA-certified diagnostic laboratory. Genotyping was carried out with the AmpFl STR SGM plus Kit (Applied Biosystems) to confirm paternity and maternity. The effects of the variants were assessed with Combined Annotation-Dependent Depletion (CADD) 11 and by determining the GERP++ scores 12, 13 .
RNA isolation, cDNA synthesis, cloning and colony PCR. Total RNA was extracted (RNeasy Mini kit, Qiagen) from cultured primary fibroblasts obtained from a skin biopsy of subjects 1 and 2. 1 µg total RNA was reverse transcribed (Superscript TM III RT, ThermoFisher) using random hexamers as primers, and 1 μl of the reverse transcription reaction was utilized to amplify a 320-bp EBF3 cDNA fragment encompassing the c.625C>T variant (forward primer 5′-ACCCACGAGATCATGTGCAG-3′, reverse primer 5′-CTGGGACTGATGGCCTTG-3′). The PCR product was directly sequenced. Exon 7 of EBF3 and adjacent intronic sequences were amplified from leukocyte-and buccal cell-derived DNA of the mother of subjects 1 and 2. The PCR product was cloned into the pCR2.1 TOPO TA Cloning Vector (ThermoFisher). Individual E.coli clones were subjected to colony PCR followed by Sanger sequencing to haplotype determination. Structural analysis. The three-dimensional structure of the DNA-binding domain of wildtype and EBF3 mutants (amino acids 50-251) was obtained by means of homology modeling using the SWISS-MODEL web-based service 14 . The crystallographic structure at 2.8-Å resolution of EBF1 bound to DNA (PDB entry 3MLP) was used as a template 15 . The selected template ensured the best homology score (95.9%). The coordinates of the DNA backbone were taken from the crystal structure of the double-stranded DNA bound to EBF1 15 . Molecular graphics were developed with UCSF Chimera software 16 .
Plasmid construction and mutagenesis. The coding region of human wild-type EBF3 (NM_001005463.2) was amplified by using EBF3-specific PCR primers and cDNA of human fetal brain as template. The forward primers were designed with a 5'-CACC overhang and lacked the start codon sequence. Purified PCR products were cloned into pENTR/D-TOPO vector (ThermoFisher) according to the manufacturer's protocol. EBF3 single mutations encoding p.His157Ala, p.Asn66Asp, p.Tyr141Cys, p.His157_Ile159dup, p.Gly171Asp, p.Pro177Leu und p.Arg209Trp were introduced into EBF3 cDNA with the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies). Subsequently, N-terminally FLAGtagged EBF3 constructs were generated by transferring the coding region into the destination vector pFLAG-CMV4-cassetteA 17 . The coding region of the mutants EBF3 Q305* and EBF3 R303* and of p53 WT was amplified by using specific PCR primers and pFLAG-CMV4-EBF3 WT and LeGO-iG2-Puro+-p53 as templates, respectively. The LeGO-iG2-Puro+-p53 construct was kindly provided by Kristoffer Rieken (University Medical Center Hamburg-Eppendorf, Hamburg, Germany). Cloning into pENTR/D-TOPO and destination vectors was performed as described above. For RNA-sequencing and ChIP-seq experiments EBF3 WT and EBF3 P177L cDNA constructs were designed and ordered as synthetic dsDNA gBlocks (IDT) and cloned into a pCMV6-3xFlag-2A-Neomycin vector (modified from pCMV6-AC-GFP, Origene) using Gibson Assembly (NEB) to yield the desired EBF3-3xFlag expression vectors ( Supplementary Fig. 7) . Full vector and cDNA sequences are available on request. All constructs were sequenced for integrity.
Cell culture and transfection. HEK 293T (human embryonic kidney) cells and primary fibroblasts were cultured in Dulbecco's modified Eagle medium (DMEM; ThermoFisher)
